Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Andrew Marks
Indiana Univ Purdue Univ at Indianapolis, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
ARMGO Pharma Inc
Payment for services (e.g., consulting fees, honoraria, paid authorship)
NA
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Our preliminary data suggest that 'leaky' Ca2+ release channels are associated with chemobrain-induced cognitive dysfunction; mice subjected to chemotherapy showed posttranslational modifications of neuronal RyR channels consistent with intracellular calcium leak and exhibited altered behavior and impaired cognitive function. From our pilot and previous studies we hypothesize that intracellular Ca2+ leak represents a key pathology that impairs memory storage and alters signaling in the brain required for normal behavior (and contributes to chemobrain). A novel drug called a rycal that we have developed which prevents intracellular Ca2+ leak will be tested in mouse models to determine whether it can prevent chemobrain-induced cognitive dysfunction.
Filed on June 21, 2016.
Tell us what you know about Andrew Marks's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Andrew Marks filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | $0 - $4,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | ARMGO Pharma Inc | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.